← SGLT2 inhibitors × cardiovascular events

TrialThe lancet. Diabetes & endocrinology2020

Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.

Megumi Oshima et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 4,401 people · 2020

Randomised comparison

Reduced cardiovascular events

−35%−45% to −23%

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.65, 95% CI 0.55–0.77

One number in the abstract

the abstract, start to end

… than the placebo group (hazard ratio 0.65, 95% CI 0.55-0.77; p<0.0001).

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.650.55–0.77
SGLT2 inhibitorsCardiovascular events

SGLT2 inhibitors × cardiovascular eventshelps?mixed

unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

70 papers cite itlatest 60 shown

2020
…
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 33065060